The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

The bladder cancer market is projected to reach $16 billion across 8 major markets (8MM) by 2033, driven by new therapies and ...

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

The NHS will roll out a new treatment for advanced bladder cancer which doubles survival time. It's estimated that 1,250 ...

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder cancer population. | Roche has found redemption in a precision medicine ...

Experts said the approval of the new treatment combination would bring a ‘fundamental shift’ in care for patients with ...